Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Relationship between four tumor-associated bio-markers and prognosis of gastric cancer

Xuyang Wen^1,2, Qianwen Li³, Yunxiang Du³, Yan Shi⁴, Jing Yuan⁵, Li Chen², Qiong Sun², Guanghai Dai²

¹Medical Oncology Department, People's Liberation Army 82nd Hospital, Huai'an 223001, Jiangsu Province, PR China; ²Medical Oncology Department, People's Liberation Army General Hospital, Beijing 100853, PR China; ³Rediotherapy Department, People's Liberation Army 82nd Hospital, Huai'an 223001, Jiangsu Province, PR China; ⁴Department of Oncology Multimodality Therapy; ⁵Department of Pathology, People's Liberation Army General Hospital, Beijing 100853, PR China.

For correspondence:- Guanghai Dai Email: guanghaidai82@163.com Tel:+861066887329

Received: 18 January 2017 Accepted: 11 May 2017 Published: 29 June 2017

Citation: Wen X, Li Q, Du Y, Shi Y, Yuan J, Chen L, et al. Relationship between four tumor-associated bio-markers and prognosis of gastric cancer. Trop J Pharm Res 2017; 16(6):1245-1251 doi: 10.4314/tjpr.v16i6.6

© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the relationship between prognosis of gastric cancer (GC) and the expression of P53, Epidermal growth factor receptor (EGFR), Human epidermal growth factor receptor-2 (HER-2), and Vascular endothelial growth factor (VEGF).

Methods: One hundred and forty-seven patients admitted to People's Liberation Army General Hospital (Beijing, China) with diagnosis of locally advanced GC were enrolled in the study. Follow-up data were obtained by outpatient review or telephone follow-up. expressions of P53, EGFR, HER-2 and VEGF were determined by immunohistochemical staining. The relationship between protein expression, clinico-pathological factors, disease-free survival time (DFS) and overall survival (OS) were analyzed.

Results: The expressions of EGER, HER-2, P53 and VEGF in GC were 17.7, 17.0, 41.0 and 55.9%, respectively. The expressions of EGFR and P53 were positively correlated (r = 0.306, p < 0.05), while the expressions of VEGF and HER-2 were negatively correlated (r = -0.2, p < 0.05). The expressions of EGFR, HER-2 and VEGF were not related to the clinico-pathological factors (p > 0.05) while expression of P53 was related only to histological grade (p < 0.05). Univariate analysis showed that OS and DFS were longer (p < 0.05) when P53 was lowly expressed. Multiple-factor analysis revealed that histological grade, infiltration depth and P53 expression were independent factors that influenced DFS.

Conclusion: These results indicate that the expression of P53, EGFR, HER2 and VEGF can be used to predict prognosis of GC and screening of patients’ benefits from adjuvant chemotherapy.

Keywords: Gastric cancer, Prognosis, Biomarkers, Adjuvant chemotherapy